HHS

HHS

Biodefense Headlines – 31 March 2025

Biosecurity March 31, 2025

This week’s topics include restructuring of ASPR, anti-vaccine leadership at NIH, the UK’s new pathogen priority research targets list, and data on a post-exposure treatment for filoviruses. FEATURED Trump Administration…

BARDA Backs Biodosimetry Tests from MRIGlobal, DxTerity Diagnostics

NuThrax: HHS Backs Next-Gen Anthrax Vaccine with 198M Contract

Phase I Study Planned for Multivalent Vaccine to Combat Ebola, Marburg

Innovation Prize Competition for Antimicrobial Resistance Diagnostics

BARDA Backs OraSure’s Rapid Zika Diagnostic

BARDA Backs Antibody Therapy Against MERS Virus

HHS Funds Rapid, High-Capacity Zika Serological Diagnostic

HHS Backs Hologic’s Zika Blood Screening Test

Pfenex Anthrax Vaccine Shows Good Early Results

Single-Dose Anthrax Vaccine Nasal Spray Clinical Trial

OrbeShield Radiation Countermeasure Gets Additional Backing

HHS Summit to Accelerate Zika Diagnostics Development

Superbugs & Superdrugs Comes to the U.S.

Burn Treatment Gets Additional Backing from BARDA

Anthrax Capsule Vaccine Shows Promise

CIADM to Accelerate Zika Vaccine Development

Emergent Passes Inspection of Anthrax Vaccine Manufacturing Facility

BARDA Backs Cerus’ Blood Pathogen Reduction System

BARDA and the Battle Against MCR-1

UVA Researchers Identify Potential Countermeasures for Radiation Exposure

Biodefense Headlines – 31 March 2025